Patents by Inventor James Robert Blinn

James Robert Blinn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLYL PYRROLO[2,3-B]PYRMIDINE-5-CARBOXYLATE ANALOGS AND METHODS OF MAKING THE SAME
    Publication number: 20190135807
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: November 2, 2018
    Publication date: May 9, 2019
    Inventors: David Randolph ANDERSON, Susan Landis HOCKERMAN, James Robert BLINN, Eric Jon JACOBSEN
  • HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER
    Publication number: 20190106439
    Abstract: Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: December 10, 2018
    Publication date: April 11, 2019
    Inventors: Eric Jon JACOBSEN, James Robert BLINN, John Robert SPRINGER, Susan Landis HOCKERMAN
  • Heterocyclic ITK inhibitors for treating inflammation and cancer
    Patent number: 10150783
    Abstract: Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: December 11, 2018
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan L. Hockerman
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180282304
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 4, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER
    Publication number: 20180208594
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: January 25, 2018
    Publication date: July 26, 2018
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan L. Hockerman, David Randolph Anderson
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180086736
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 29, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER
    Publication number: 20170260211
    Abstract: Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: May 31, 2017
    Publication date: September 14, 2017
    Inventors: Eric Jon JACOBSEN, James Robert BLINN, John Robert SPRINGER, Susan L. HOCKERMAN
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20170233371
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: April 26, 2017
    Publication date: August 17, 2017
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Gõran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, Jr., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Heterocyclic ITK inhibitors for treating inflammation and cancer
    Patent number: 9695200
    Abstract: Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: July 4, 2017
    Assignee: Confluence Life Sciences, Inc.
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan L. Hockerman
  • 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
    Patent number: 9505765
    Abstract: 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds, pharmaceutically acceptable salts, solvates and pharmaceutical compositions of compounds embraced by Formula (I), provide a therapeutic benefit to subjects with disease conditions, especially cancer, wherein R1 and R2 are as defined in the detailed description.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: November 29, 2016
    Assignee: CONFLUENCE LIFE SCIENCES INC.
    Inventors: Eric Jonathan Jacobsen, John Robert Springer, James Robert Blinn, Balekudru Devadas
  • Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases
    Patent number: 9499551
    Abstract: Disclosed herein are substituted pyrrolopyridine and pyrrolopyrazine compounds and compositions useful in the treatment of TAK mediated diseases, such as cancer, having the structure of Formula (I): wherein R1, R2, R3, and R4 are as defined in the detailed description. Methods of modulation of TAK activity in a human or animal subject are also provided, providing therapeutic benefit to subjects with disease conditions, especially cancer.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 22, 2016
    Assignee: Confluence Life Sciences, Inc.
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan L. Hockerman
  • HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER
    Publication number: 20160213653
    Abstract: Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: January 25, 2016
    Publication date: July 28, 2016
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan L. Hockerman
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20160046597
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 18, 2016
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER
    Publication number: 20150328227
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 22, 2015
    Publication date: November 19, 2015
    Inventors: Eric Jon Jacobsen, James Robert Blinn
  • Arylpyridinone ITK inhibitors for treating inflammation and cancer
    Patent number: 9145393
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: September 29, 2015
    Assignee: Confluence Life Sciences, Inc.
    Inventors: Eric Jon Jacobsen, James Robert Blinn
  • ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER
    Publication number: 20150210671
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 30, 2015
    Inventors: Eric Jon Jacobsen, James Robert Blinn
  • SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES
    Publication number: 20150210705
    Abstract: Disclosed herein are substituted pyrrolopyridine and pyrrolopyrazine compounds and compositions useful in the treatment of TAK mediated diseases, such as cancer, having the structure of Formula (I): wherein R1, R2, R3, and R4 are as defined in the detailed description. Methods of modulation of TAK activity in a human or animal subject are also provided, providing therapeutic benefit to subjects with disease conditions, especially cancer.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 30, 2015
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan L. Hockerman
  • 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT
    Publication number: 20150203499
    Abstract: The present disclosure provides 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds, pharmaceutically acceptable salts, solvates and pharmaceutical compositions of compounds embraced by Formula (I), providing a therapeutic benefit to subjects with disease conditions, especially cancer, wherein R1 and R2 are as defined in the detailed description.
    Type: Application
    Filed: July 26, 2013
    Publication date: July 23, 2015
    Inventors: Eric Jonathan Jacobsen, John Robert Springer, James Robert Blinn, Balekudru Devadas